Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2018 Apr 5

PMID 29616047

Citations 32

Authors

Gillian L Dornan

John E Burke

Affiliations

Soon will be listed here.

Abstract

The signaling lipid phosphatidylinositol 3,4,5, trisphosphate (PIP) is an essential mediator of many vital cellular processes, including growth, survival, and metabolism. PIP is generated through the action of the class I phosphoinositide 3-kinases (PI3K), and their activity is tightly controlled through interactions with regulatory proteins and activating stimuli. The class IA PI3Ks are composed of three distinct p110 catalytic subunits (p110α, p110β, and p110δ), and they play different roles in specific tissues due to disparities in both expression and engagement downstream of cell-surface receptors. Disruption of PI3K regulation is a frequent driver of numerous human diseases. Activating mutations in the gene encoding the p110α catalytic subunit of class IA PI3K are frequently mutated in several cancer types, and mutations in the gene encoding the p110δ catalytic subunit have been identified in primary immunodeficiency patients. All class IA p110 subunits interact with p85 regulatory subunits, and mutations/deletions in different p85 regulatory subunits have been identified in both cancer and primary immunodeficiencies. In this review, we will summarize our current understanding for the molecular basis of how class IA PI3K catalytic activity is regulated by p85 regulatory subunits, and how activating mutations in the PI3K catalytic subunits and (p110α, p110δ) and regulatory subunits (p85α) mediate PI3K activation and human disease.

Citing Articles

High Frequency of Alterations in Ovarian Cancers: Clinicopathological and Molecular Associations.

Rzepecka I, Tysarowski A, Konopka B, Dansonka-Mieszkowska A, Kupryjanczyk J Cancers (Basel). 2025; 17(2).

PMID: 39858051 PMC: 11764438. DOI: 10.3390/cancers17020269.

When, where and which PIK3CA mutations are pathogenic in congenital disorders.

Angulo-Urarte A, Graupera M Nat Cardiovasc Res. 2024; 1(8):700-714.

PMID: 39196083 DOI: 10.1038/s44161-022-00107-8.

Upregulation of MMPs in placentas of patients with gestational diabetes mellitus: Involvement of the PI3K/Akt pathway.

Zhang Y, Liu Y, Shi Y, Bai C, Wang T, Ruan F Heliyon. 2024; 10(12):e32518.

PMID: 39021921 PMC: 11252657. DOI: 10.1016/j.heliyon.2024.e32518.

Mapping variant effects on anti-tumor hallmarks of primary human T cells with base-editing screens.

Walsh Z, Shah P, Kothapalli N, Shah S, Nikolenyi G, Brodtman D Nat Biotechnol. 2024; .

PMID: 38783148 DOI: 10.1038/s41587-024-02235-x.

A deep learning-based theoretical protocol to identify potentially isoform-selective PI3Kα inhibitors.

Shafiq M, Sherwani Z, Mushtaq M, Nur-E-Alam M, Ahmad A, Ul-Haq Z Mol Divers. 2024; 28(4):1907-1924.

PMID: 38305819 DOI: 10.1007/s11030-023-10799-0.

References

Hirsch E, Katanaev V, Garlanda C, Azzolino O, Pirola L, Silengo L . Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science. 2000; 287(5455):1049-53. DOI: 10.1126/science.287.5455.1049. View

Pacold M, Suire S, Perisic O, Davis C, WALKER E, Hawkins P . Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell. 2001; 103(6):931-43. DOI: 10.1016/s0092-8674(00)00196-3. View

Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, Peskett E . Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science. 2002; 297(5583):1031-4. DOI: 10.1126/science.1073560. View

Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S . High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004; 304(5670):554. DOI: 10.1126/science.1096502. View

Knight Z, Gonzalez B, Feldman M, Zunder E, Goldenberg D, Williams O . A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006; 125(4):733-47. PMC: 2946820. DOI: 10.1016/j.cell.2006.03.035. View

Zhao J, Cheng H, Jia S, Wang L, Gjoerup O, Mikami A . The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc Natl Acad Sci U S A. 2006; 103(44):16296-300. PMC: 1637576. DOI: 10.1073/pnas.0607899103. View

Gymnopoulos M, Elsliger M, Vogt P . Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci U S A. 2007; 104(13):5569-74. PMC: 1838453. DOI: 10.1073/pnas.0701005104. View

Geering B, Cutillas P, Nock G, Gharbi S, Vanhaesebroeck B . Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers. Proc Natl Acad Sci U S A. 2007; 104(19):7809-14. PMC: 1876529. DOI: 10.1073/pnas.0700373104. View

Deindl S, Kadlecek T, Brdicka T, Cao X, Weiss A, Kuriyan J . Structural basis for the inhibition of tyrosine kinase activity of ZAP-70. Cell. 2007; 129(4):735-46. DOI: 10.1016/j.cell.2007.03.039. View

10.

Gupta S, Ramjaun A, Haiko P, Wang Y, Warne P, Nicke B . Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell. 2007; 129(5):957-68. DOI: 10.1016/j.cell.2007.03.051. View

11.

Miled N, Yan Y, Hon W, Perisic O, Zvelebil M, Inbar Y . Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science. 2007; 317(5835):239-42. DOI: 10.1126/science.1135394. View

12.

Huang C, Mandelker D, Schmidt-Kittler O, Samuels Y, Velculescu V, Kinzler K . The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science. 2007; 318(5857):1744-8. DOI: 10.1126/science.1150799. View

13.

Zhao L, Vogt P . Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A. 2008; 105(7):2652-7. PMC: 2268191. DOI: 10.1073/pnas.0712169105. View

14.

Kok K, Geering B, Vanhaesebroeck B . Regulation of phosphoinositide 3-kinase expression in health and disease. Trends Biochem Sci. 2009; 34(3):115-27. DOI: 10.1016/j.tibs.2009.01.003. View

15.

Mandelker D, Gabelli S, Schmidt-Kittler O, Zhu J, Cheong I, Huang C . A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane. Proc Natl Acad Sci U S A. 2009; 106(40):16996-7001. PMC: 2761334. DOI: 10.1073/pnas.0908444106. View

16.

Jaiswal B, Janakiraman V, Kljavin N, Chaudhuri S, Stern H, Wang W . Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell. 2009; 16(6):463-74. PMC: 2804903. DOI: 10.1016/j.ccr.2009.10.016. View

17.

Dbouk H, Pang H, Fiser A, Backer J . A biochemical mechanism for the oncogenic potential of the p110beta catalytic subunit of phosphoinositide 3-kinase. Proc Natl Acad Sci U S A. 2010; 107(46):19897-902. PMC: 2993364. DOI: 10.1073/pnas.1008739107. View

18.

Rudd M, Price J, Fogoros S, Godwin A, Sgroi D, Merino M . A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res. 2011; 17(6):1331-40. PMC: 3060282. DOI: 10.1158/1078-0432.CCR-10-0540. View

19.

Zhang X, Vadas O, Perisic O, Anderson K, Clark J, Hawkins P . Structure of lipid kinase p110β/p85β elucidates an unusual SH2-domain-mediated inhibitory mechanism. Mol Cell. 2011; 41(5):567-78. PMC: 3670040. DOI: 10.1016/j.molcel.2011.01.026. View

20.

Urick M, Rudd M, Godwin A, Sgroi D, Merino M, Bell D . PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res. 2011; 71(12):4061-7. PMC: 3117071. DOI: 10.1158/0008-5472.CAN-11-0549. View